Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity

Area of Science:

• Veterinary Medicine
• Allergy and Immunology
• Toxicology

Background:

• Hymenoptera envenomation frequently causes anaphylaxis in dogs.
• Venom immunotherapy (VIT) is the only preventive treatment for Hymenoptera hypersensitivity in humans.
• Rush VIT, an accelerated protocol, is established in humans but not reported in dogs.

Purpose of the Study:

• To evaluate the safety and tolerability of a modified rush VIT protocol in dogs.
• To assess adverse reactions associated with accelerated VIT in canine patients.

Main Methods:

• Twenty client-owned dogs diagnosed with Hymenoptera hypersensitivity were enrolled.
• Dogs received weekly subcutaneous injections of venom over three weeks to reach maintenance dosage.
• Vital signs were monitored, and adverse reactions were classified as localized or systemic (Grades I-IV).

Main Results:

• Nineteen out of twenty dogs (95%) successfully completed the modified rush VIT protocol.
• One dog experienced a Grade III systemic reaction and was withdrawn.
• Fifty percent of dogs had no adverse reactions; 45% experienced localized or mild (Grade I-II) systemic reactions.

Conclusions:

• Modified rush VIT is a well-tolerated treatment option for dogs with Hymenoptera hypersensitivity.
• The protocol shows promise for preventing severe hypersensitivity reactions to insect stings in dogs.
• Further research is required to establish the efficacy of VIT in canine Hymenoptera allergy.